Clinical trial

Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation

Name
ME 10 0054
Description
The goal of this research is to demonstrate the use of petroleum jelly in prevention of nonscalp seborrheic dermatitis exacerbations at the first signs of a flare. In doing so, it will decrease the chronic use of topical steroids. The use of petrolatum should have favorable outcomes for patients, without the side-effects.
Trial arms
Trial start
2011-03-01
Estimated PCD
2012-02-01
Trial end
2012-03-01
Status
Terminated
Treatment
Petroleum Jelly
Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
Arms:
Petroleum Jelly
Other names:
Petrolatum, Vaseline
Size
3
Primary endpoint
Measuring the Effectiveness of Petroleum Jelly in Treating Nonscalp Seborrheic Dermatitis
4 weeks
Eligibility criteria
Inclusion Criteria: * Age 18-75 years old who are patients of the Genesys East Flint Clinic and have been diagnosed with recurrent NSSD * Patients are to use the petrolatum treatment strictly for the initial symptoms of NSSD: Excessive flaking, and erythematous macules or papules * Patients who are able to attend the follow-up appointments for assessment * Patients are to have the doctor's confidence that that patient will correctly implement the treatment plan Exclusion Criteria: * Patients not in the 18-75 years of age range. * Patients who are receiving treatment for their seborrheic dermatitis (Scalp or nonscalp) elsewhere. * Patients who have not demonstrated recurrent NSSD. * Patients who are unable to commit to a follow-up appointments for assessment. * Patients who do not have the physician's confidence in implementing the studies treatment plan effectively. * Patient's who are unable/unwilling to have petrolatum on affected area for at least a 6 hour length of time.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 3, 'type': 'ACTUAL'}}
Updated at
2024-05-20

1 organization

1 product

1 indication

Organization
Ascension Health